AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06184815 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational programme 12
Description: Consists of 12 lessons, diabetes education slides and patient materials, with a duration of 4 months and multidisciplinary treatment
Study NCT06184815 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard education and treatment
Description: Outpatient management and education in the office and consultation referral to nutrition and psychology
Study NCT05152901 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EpiPen ®.
Description: A single dose of 0.3 mg epinephrine via intramuscular injection into the anterolateral aspect of the thigh on Day 1 Visit 2.
Study NCT04990388 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: consists of the same components as the formulation buffer for UX053
Study NCT06390540 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: During the training, verbal information will be given about the importance of exercise, exercise barriers, and the potential benefits of exercise on the mother and baby in the postpartum period. In the training, the points that the mother should pay attention to before exercise will also be discussed. In the following process, videos containing deep breathing and relaxation exercises will be sent to women. The videos will be recorded by the researchers at Ankara University Physiotherapy application laboratory. Recording videos will be delivered to women through social networks. Women will be allowed to do these exercises for a total of 8 weeks.
Study NCT06607146 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sound Success
Description: Subjects will be instructed to perform auditory training with the Sound Success computer-based auditory training program. This is a free program that requires a brief account registration. Subjects will be instructed to perform auditory training on a personal device and will be recommended a target usage of at least 30 minutes 5 times per week.
Study NCT06607146 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care
Description: Subjects will be provided a list of common exercises for auditory training. This is the current standard of care at our institution.
Study NCT06607094 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rezum
Description: The Rezum System is designed to treat patients with urinary symptoms associated with BPH. The Rezum System utilizes radiofrequency current to generate thermal energy in the form of water vapor, which is then injected into the transition zone and/or median lobe of the prostate in controlled 9-second doses. The vapor injected into the prostate tissue rapidly disperses through the interstitial space between the tissue cells. As the vapor cools, it condenses immediately on contact with tissue, and the stored thermal energy is released, denaturing the cell membranes and causing cell death.
Study NCT06608797 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Learning and memory training
Description: The experimental group will receive memory retraining exercises administered on a laptop computer via Zoom Health twice a week for five weeks (10 training sessions).
Study NCT06608797 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham Comparator
Description: The sham comparator group will receive sham memory exercises administered on a laptop computer via Zoom Health twice a week for five weeks (10 placebo control sessions).
Study NCT06594991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fianlimab
Description: Fianlimab IV given every three weeks
Study NCT06594991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Cemiplimab IV given every three weeks
Study NCT06594991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab will be give every 6 weeks continuously
Study NCT06600386 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Alveolar recruitement
Description: PEEP after alveolar reruitment maneuvres
Study NCT06600386 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard PEEP
Description: PEEP 5 cmH2O
Study NCT05725837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paroxetine
Description: Paroxetine, 40mg/day, once a day, for 05 consecutive days or 24 hours after shock resolution
Study NCT04990388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antipyretic
Description: participants will receive oral premedication prior to infusion
Study NCT04990388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H2 Blocker
Description: participants will receive oral premedication prior to infusion
Study NCT04990388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H1 Blocker
Description: participants will receive oral premedication prior to infusion
Study NCT05725837 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paroxetine
Description: Paroxetine, 40mg/day, once a day, for 05 consecutive days or 24 hours after shock resolution
Study NCT05743426 — intervention group
Intervention type: OTHER
Intervention: Survey
Description: Patient Reported Outcome (PRO) questionnaire
Study NCT05743426 — intervention group
Intervention type: OTHER
Intervention: Toxicity Assessments
Description: Toxicity Assessments will be performed using the National Cancer Institute Common Terminology Criteria (NCI-CTCAE).
Study NCT05987774 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AI Modules for Improving Social Conversation
Description: The application if the modules will be delivered using software. These modules have been developed to provide feedback on specific areas following voice or text input (user preference will be recorded in case this effects the results).~The investigators currently have developed AI modules for common social communication challenges exhibited by individuals with ASD. Examples include:~Empathy (general and in the work setting), Asking Relevant Questions, Listen and Respond, Talking the right amount, giving the right amount of personal information, Tactful Responses, Giving compliments, and Staying on topic during Conversation. These are all areas that can be challenging for individuals diagnosed with autism spectrum disorder.~AI modules consist of thousands of total training examples. Participants may access the modules on their phones or computers.
Study NCT06510673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platelet rich plasma
Description: Platelet-rich plasma for the heel
Study NCT06510673 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High power LASER
Description: High power LASER sessions for the heel
Study NCT06510673 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shockwave therapy
Description: Shockwave therapy sessions for the heel
Study NCT06510673 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Ice application
Description: Ice application for the heel
Study NCT06510673 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham LASER
Description: Sham LASER for the heel
Study NCT06270862 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resilience training
Description: Receive mini course on what is resilience and how to use different exercises to be more resilient in life.
Study NCT06270862 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive training
Description: Play games that trains attention, memory and planning using the services provided by CogniFit.
Study NCT06270862 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: cognitive training
Description: Play games that trains attention, memory and planning using the services provided by CogniFit.
Study NCT06270862 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: physical exercise
Description: Engage in age-appropriate physical exercises.
Study NCT06270862 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: physical exercise
Description: Engage in age-appropriate physical exercises.
Study NCT06270862 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: social interaction
Description: Engage in social discussion with peers in the group.
Study NCT06270862 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: social interaction
Description: Engage in social discussion with peers in the group.
Study NCT06270862 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: workshop series
Description: Watch a series of workshops targeting the older adult population.
Study NCT06607237 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DM-28
Description: 1 drop in each eye, 4 to 6 times per day
Study NCT06604793 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Creatine
Description: Creatine monohydrate
Study NCT06604793 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maltodextrin
Study NCT06607107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOX7 combined with Camrelizumab and apatinib
Description: mFOLFOX7(Oxaliplatin 85mg/m2, Calcium Levofolinate 200mg/m2, Fluorouracil 400 mg/m2 D1，2400mg/m2 maintain 46 hours，) combined with Apatinib and Camrelizumab 200mg every 3 weeks. Taking Apatinib-Mesylate Tablets (250 mg/tablet) orally after meals, once a day, for continuous medication.
Study NCT06246656 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Maxillary Expansion
Description: Palatal Expansion using a CAD/CAM appliance
Study NCT05611372 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rasagiline
Description: 1 mg rasagiline
Study NCT05611372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rasagiline
Description: 1 mg rasagiline
Study NCT06616311 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiofrequency microneedling
Description: The target population is skin of color patients with melasma. Patients will receive 5 consecutive RFMN treatments over a period of 5 months.
Study NCT06671704 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Genetic counseling months 4-15
Description: all genetic counselors within the same specialty at the same site will cross over from standard of care to the intervention training starting at month 4 to month 15.
Study NCT06671704 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Genetic counseling months 6-15
Description: all genetic counselors within the same specialty at the same site will cross over from standard of care to the intervention training starting at month 6 to month 15.
Study NCT06671704 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Genetic counseling months 8-15
Description: all genetic counselors within the same specialty at the same site will cross over from standard of care to the intervention training starting at month 8 to month 15.
Study NCT06671704 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Genetic counseling at months 10-15
Description: all genetic counselors within the same specialty at the same site will cross over from standard of care to the intervention training starting at month 10 to month 15.
Study NCT06671704 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Genetic counseling at months 12-15
Description: all genetic counselors within the same specialty at the same site will cross over from standard of care to the intervention training starting at month 12 to month 15.
Study NCT06671704 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Genetic counseling at months 14-15
Description: all genetic counselors within the same specialty at the same site will cross over from standard of care to the intervention training starting at month 14 to month 15.
Study NCT04827732 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Pencil-Beam Scanning Intensity-modulated Proton Therapy
Description: When feasible it is strongly recommended that radiotherapy begin on a Monday
Study NCT04827732 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MEVION S250i Hyperscan and Adaptive Aperture Proton Therapy Machine
Description: -The device that will administer the IMPT
Study NCT06681389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NP-201 acetate injection (Part A)
Description: Route of administration- Sub cutaneous. Dosage interval and frequency: MAD1-200mg daily for 5 days; MAD2- 300mg daily for 5 days, MAD3- 400mg daily for 5 days
Study NCT06681389 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo administered across Part A and Part B
Study NCT04752696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Onvansertib
Description: Oral capsule
Study NCT04752696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nanoliposomal irinotecan
Description: Intravenous infusion
Study NCT05152901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinephrine (0.3mg) inhaled
Description: Participants will be administered 0.3mg of first inhaled dose of epinephrine once daily on day 2 of Visit 2
Study NCT05152901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinephrine (1.3mg)
Description: A single inhaled dose or split into 2 administrations (administered less than 1 minute apart) of a planned dose of 1.3 mg epinephrine.
Study NCT05152901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinephrine (4mg)
Description: A single inhaled dose or split into 2 administrations (administered less than 1 minute apart) of a planned dose of 4 mg epinephrine
Study NCT05490745 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Skills4Parenting+
Description: Skills4Parenting+ has 6-8 weekly individual online sessions (50 min) + 8-week follow-up. First, an assessment session of parents' positive parenting skills (PPS), based on mother/father-child interaction observation. The following sessions aim to (1) promote parental reflective functioning, enhancing parents' understanding of the child´s problems, and (2) activate PPS to solve the child's problems. Written registers of problematic situations - in which the problems of the child occur, are analyzed (i.e., child's and parents' behaviors, thoughts, and feelings) (intersession activity) - are reflected upon, to understand and solve through PPS. PPS implementations are analyzed to understand the changes in the child and parent. Future situations and activation of appropriate PPS are anticipated, to solve potential upcoming problems of the child's, related to adversity. When the therapeutic goals have not been fully achieved, two additional sessions (total of 8 instead of 6), are added.
Study NCT05490745 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Waiting-list (nocebo)
Description: Participants wait to receive the psychological intervention (Skills4Parenting+) for eight weeks, after the assessment session.
Study NCT06291025 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PEX-FREE
Description: The study/experimental procedure consists in replacing daily PEX with daily plasma infusions (ie. Quarantine fresh frozen plasma (PFC-Se), solvent detergent/viral inactivated plasma (PFC-SD = OCTAPLASLG) or amotosalen-inactivated plasma (PFC-IA); volume 15mL/kg/day).
Study NCT05859789 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: kegel exercise
Description: * Each female will be asked to Try to squeeze her pelvic floor muscles as much as possible. She was instructed that the numbers she saw at the top of screen indicated the activity of the muscle (electrical activity), in microvolt (mv).~* The therapeutic session will be repeated 3 sessions /week for 12 weeks for each female in both groups (A\&B).~* Each female will be instructed to Tighten her pelvic floor muscles. Hold tight and count 3 to 5 seconds, relax the muscles and count 3 to 5 seconds, then repeat 10 times, 3 times a day at least three sets of 10 to 15 repetitions a day as a home program~* They will be instructed not to use abdomen, thighs or buttock muscles during the contraction, avoid holding breath. Instead, breathe freely during the exercises.
Study NCT05859789 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: kegel exercise
Description: * Each female will be asked to Try to squeeze her pelvic floor muscles as much as possible. She was instructed that the numbers she saw at the top of screen indicated the activity of the muscle (electrical activity), in microvolt (mv).~* The therapeutic session will be repeated 3 sessions /week for 12 weeks for each female in both groups (A\&B).~* Each female will be instructed to Tighten her pelvic floor muscles. Hold tight and count 3 to 5 seconds, relax the muscles and count 3 to 5 seconds, then repeat 10 times, 3 times a day at least three sets of 10 to 15 repetitions a day as a home program~* They will be instructed not to use abdomen, thighs or buttock muscles during the contraction, avoid holding breath. Instead, breathe freely during the exercises.
Study NCT05859789 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mediterranean diet regimen for 12 weeks.
Description: kegel ex in addition to mediterrian diet . The recommended composition of the dietary regimen was the following: carbohydrates 50-60%, proteins 15-20%, total fat o30%, saturated fat 10% and less than 300 mg of cholesterol consumed per day. Moreover, subjects Will be advised to consume at least 250-300 g of fruits, 125-150 g of vegetables and 25-50 g of nuts per day.
Study NCT05390957 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance Based Behavioural Therapy - Revised
Description: The study intervention is a revised, updated version of a previously studied eight-module (8-week) online, acceptance-based behavioural therapy (ABBT) for chronic pain that was tailored specifically to a military, RCMP, and veteran population. The online treatment material is administered via the WebCAPSI Therapy program.
Study NCT05241067 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Placebo (Dose: equal volume saline) + Standard of care
Study NCT05241067 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Centhaquine
Description: Centhaquine (Dose: 0.01 mg/kg) + Standard of care
Study NCT04752696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Intravenous infusion
Study NCT04752696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Intravenous infusion
Study NCT06699212 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: ASP-1929 Photoimmunotherapy
Description: ASP-1929 IV infusion followed by illumination with light dose of 50 J/cm\^2 for superficial lesions and 100 J/cm for interstitial lesions within 24 +/- 4 hours after the end of ASP-1929 infusion (up to 24 months)
Study NCT06699212 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg Q3W or 400 mg Q6W, IV infusion over 30 minutes (up to 24 months)
Study NCT06699212 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: 200 mg Q3W or 400 mg Q6W, IV infusion over 30 minutes (up to 24 months)
Study NCT06699212 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Area under the curve (AUC) 5 mg/mL/min IV infusion, Q3W up to 6 cycles
Study NCT06699212 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: 100 mg/m\^2 IV infusion, Q3W up to 6 cycles
Study NCT06699212 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-fluorouracil
Description: 1000 mg/m\^2 per day from Days 1-4 of each cycle, IV infusion, Q3W up to 6 cycles
Study NCT06699212 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: 100 mg/m\^2 IV infusion given on Days 1 and 8, Q3W up to 6 cycles or 175 mg/m\^2 IV infusion given on Day 1, Q3W up to 6 cycles
Study NCT06699212 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: 75 mg/m\^2 IV Infusion, Q3W up to 6 cycles
Study NCT06755528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chitosan
Description: The participants will receive medications for fallopian tube adhesions (Chitosan (glucosamine (GIcN) and N-acetylglucosamine (GIcNAc) units,1 tablet per day) as prescribed by the gynecologist
Study NCT06755528 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chitosan
Description: The participants will receive medications for fallopian tube adhesions (Chitosan (glucosamine (GIcN) and N-acetylglucosamine (GIcNAc) units,1 tablet per day) as prescribed by the gynecologist
Study NCT06755528 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: shockwave therapy
Description: The participants will receive shockwave with the following parameters: sonic pulses characterized by: high peak pressure, up to 100 mpa (500 bar) or even more, rapid rise in pressure (\<10 ns), short duration (\<10 μs) and a broad range of frequency. The energy flux density was 0.09 to 0.16 mJ/mm2; with a frequency of 5 Hz and 2000 impulses, i session per week for 4 weeks.
Study NCT06757400 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mobilization
Description: Mobilization will be conducted on an examination table with the subject in prone position. Therapist will place his hypothenar to the most hypomobile lumbar spine segment after assessment.It will be a posteroanterior (PA) direction tecnique, Maitland's GRADE 4, 3 sets of 60 seconds duration for each set.
Study NCT06757400 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobilization
Description: Mobilization will be conducted on an examination table with the subject in prone position. Therapist will place his hypothenar to the most hypomobile lumbar spine segment after assessment.It will be a posteroanterior (PA) direction tecnique, Maitland's GRADE 4, 3 sets of 60 seconds duration for each set.